Michele Simonato

Michele Simonato

Auto-generated profile, based on publicly available information

Michele Simonato

Department of Neuroscience and Rehabilitation University of Ferrara Ferrara Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in The Lancet Neurology
Verified
Journal Article
Open access
APAsla Pitkänen
Asla Pitkänen
WLWolfgang Löscher
Wolfgang Löscher
AVAnnamaria Vezzani
Annamaria Vezzani
ABAlbert J Becker
Albert J Becker
MSMichele Simonato
Michele Simonato
HBHeinz Beck
Heinz Beck
Over 50 million people worldwide have epilepsy. In nearly 30% of these cases, epilepsy remains unsatisfactorily controlled despite the availability of over 20 antiepileptic drugs. Moreover, no treatments exist to prevent the development of epilepsy in those at risk, despite an increasing understanding of the underlying molecular and cellular pathways. One of the major factors that have impeded rapid progress in these areas is the complex and multifactorial nature of epilepsy, and its heterogeneity. Therefore, the vision of developing targeted treatments for epilepsy relies upon the development of biomarkers that allow individually tailored treatment. Biomarkers for epilepsy typically fall into two broad categories: diagnostic biomarkers, which provide information on the clinical status of, and potentially the sensitivity to, specific treatments, and prognostic biomarkers, which allow prediction of future clinical features, such as the speed of progression, severity of epilepsy, development of comorbidities, or prediction of remission or cure. Prognostic biomarkers are of particular importance because they could be used to identify which patients will develop epilepsy and which might benefit from preventive treatments. Biomarker research faces several challenges; however, biomarkers could substantially improve the management of people with epilepsy and could lead to prevention in the right person at the right time, rather than just symptomatic treatment.

23 April 2013 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MSMichele Simonato
Michele Simonato
JBJean Bennett
Jean Bennett
NBNicholas M. Boulis
Nicholas M. Boulis
MCMaria G. Castro
Maria G. Castro
DFDavid J. Fink
David J. Fink
JGJoseph C. Glorioso
Joseph C. Glorioso

23 January 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MJMichael R. Johnson
Michael R. Johnson
JBJacques Behmoaras
Jacques Behmoaras
LBLeonardo Bottolo
Leonardo Bottolo
MKMichelle L. Krishnan
Michelle L. Krishnan
KPKatharina Pernhorst
Katharina Pernhorst
EPEnrico Petretto
Enrico Petretto
Gene-regulatory network analysis is a powerful approach to elucidate the molecular processes and pathways underlying complex disease. Here we employ systems genetics approaches to characterize the genetic regulation of pathophysiological pathways in human temporal lobe epilepsy (TLE). Using surgically acquired hippocampi from 129 TLE patients, we identify a gene-regulatory network genetically associated with epilepsy that contains a specialized, highly expressed transcriptional module encoding proconvulsive cytokines and Toll-like receptor signalling genes. RNA sequencing analysis in a mouse model of TLE using 100 epileptic and 100 control hippocampi shows the proconvulsive module is preserved across-species, specific to the epileptic hippocampus and upregulated in chronic epilepsy. In the TLE patients, we map the trans-acting genetic control of this proconvulsive module to Sestrin 3 (SESN3), and demonstrate that SESN3 positively regulates the module in macrophages, microglia and neurons. Morpholino-mediated Sesn3 knockdown in zebrafish confirms the regulation of the transcriptional module, and attenuates chemically induced behavioural seizures in vivo.

1 January 2008 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
CCC. Chiaruttini
C. Chiaruttini
MSMaura Sonego
Maura Sonego
GBGabriele Baj
Gabriele Baj
MSM. Simonato
M. Simonato
Enrico TongiorgiEnrico Tongiorgi
Enrico Tongiorgi

28 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
BPBeatrice Paradiso
Beatrice Paradiso
Marconi PeggyMarconi Peggy
Marconi Peggy
SZSilvia Zucchini
Silvia Zucchini
EBElena Berto
Elena Berto
ABAnna Binaschi
Anna Binaschi
MSMichele Simonato
Michele Simonato
A loss of neurons is observed in the hippocampus of many patients with epilepsies of temporal lobe origin. It has been hypothesized that damage limitation or repair, for example using neurotrophic factors (NTFs), may prevent the transformation of a normal tissue into epileptic (epileptogenesis). Here, we used viral vectors to locally supplement two NTFs, fibroblast growth factor–2 (FGF-2) and brain-derived neurotrophic factor (BDNF), when epileptogenic damage was already in place. These vectors were first characterized in vitro, where they increased proliferation of neural progenitors and favored their differentiation into neurons, and they were then tested in a model of status epilepticus-induced neurodegeneration and epileptogenesis. When injected in a lesioned hippocampus, FGF-2/BDNF expressing vectors increased neuronogenesis, embanked neuronal damage, and reduced epileptogenesis. It is concluded that reduction of damage reduces epileptogenesis and that supplementing specific NTFs in lesion areas represents a new approach to the therapy of neuronal damage and of its consequences.

28 July 2004 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
Enrico TongiorgiEnrico Tongiorgi
Enrico Tongiorgi
MAMara Armellin
Mara Armellin
Piero Giulio GiulianiniPiero Giulio Giulianini
Piero Giulio Giulianini
GBGianni Bregola
Gianni Bregola
SZSilvia Zucchini
Silvia Zucchini
MSMichele Simonato
Michele Simonato
Dendritic targeting of mRNA and local protein synthesis are mechanisms that enable neurons to deliver proteins to specific postsynaptic sites. Here, we demonstrate that epileptogenic stimuli induce a dramatic accumulation of BDNF mRNA and protein in the dendrites of hippocampal neuronsin vivo. BDNF mRNA and protein accumulate in dendrites in all hippocampal subfields after pilocarpine seizures and in selected subfields after other epileptogenic stimuli (kainate and kindling). BDNF accumulates selectively in discrete dendritic laminas, suggesting targeting to synapses that are active during seizures. Dendritic targeting of BDNF mRNA occurs during the time when the cellular changes that underlie epilepsy are occurring and is not seen after intense stimuli that are non-epileptogenic, including electroconvulsive seizures and high-frequency stimulation. MK801, an NMDA receptor antagonist that can prevent epileptogenesis but not acute seizures, prevents the dendritic accumulation of BDNF mRNA, indicating that dendritic targeting is mediated via NMDA receptor activation. Together, these results suggest that dendritic accumulation of BDNF mRNA and protein play a critical role in the cellular changes leading to epilepsy.